Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?
|
|
- Deirdre Briggs
- 6 years ago
- Views:
Transcription
1 Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fabrizio Ammirati Dipartimento Medicina UOC Cardiologia Ospedale GB Grassi ASL Roma 3 Sept 2013
2 Patients with AF are at increased risk of stroke and related complications if not appropriately anticoagulated 2x in mortality in patients with AF vs those without 2 Every 5 strokes 1 happens in patient with AF Without anticoagulation treatment ~ 5% of patients with AF will have a stroke every year 1 in disability including aphasia, severe limb weakness and diminished alertness in AF- vs non-af-related stroke 3,4 1. Atrial Fibrillation Investigators. Arch Intern Med 1994; 2. Benjamin EJ et al. Circulation 1998; 3. Lin HJ et al. Stroke 1996; 4. Dulli DA et al. Neuroepidemiology 2003 Sept 2013
3 Insula injury and risk of cardiac arrhythmias and death in acute stroke Pts. with vascular hystory Pts. without vascular hystory Ins - Ins + Ins - Ins + Ins - : no insula lesion Ins + : insula lesion The cortex of the Insula is known to activate the central autonomic network and may trigger arrythymias Abboud H et al., Ann Neurol 2006;59:691-99
4
5 Chicken-Egg dilemma
6 Stroke risk persists even in symptomatic/ paroxysmal AF The risk of stroke with asymptomatic or paroxysmal AF is comparable to that with permanent AF 1,2 Annual risk of stroke (%) Observed rate of ischaemic stroke 1 Intermittent AF Sustained AF Low Moderate High Stroke risk category 1. Hart RG et al. J Am Coll Cardiol 2000;35:183 7; 2. Flaker GC et al. Am Heart J 2005;149: Dec 2011
7 Relation between AF and Stroke Background Among patients with implantable pacemakers and defibrillators, subclinical atrial fibrillation (SCAF) is associated with an increased risk of stroke; however, there is limited understanding of their temporal relationship. Of 51 patients who experienced stroke or systemic embolism during follow-up, 26 (51%) had SCAF. In 18 patients (35%), SCAF was detected before stroke or systemic embolism. only 4 patients (8%) had SCAF detected within 30 days before stroke or systemic embolism, and only 1 of these 4 patients was experiencing SCAF at the time of the stroke. Conclusions Although SCAF is associated with an increased risk of stroke and embolism, very few patients had SCAF in the month before their event. M. Brambatti, Circulation 2014
8 Temporal Relationship of Atrial Fibrillation & Thromboembolism Although AT burden was associated with thromboembolism, there was no temporal relationship between AT and stroke. 29 pts with TE event and AF AF Burden (0 to 100%, log scale) Months from TE
9 Temporal Relationship of Atrial Fibrillation & Thromboembolism AF Burden (0 to 100%, log scale) Months from TE
10 Temporal Proximity of Silent AF Episodes to Thromboembolic Event Trial AF prior to stroke (at any time) AF prior to stroke (<30 days) New AF after stroke TRENDS (Daoud EG, et al Heart Rhythm 2011;8: ) ASSERT (Brambatti M et al Circulation 2014 Mar 14) IMPACT (all) Martin DT, ACC Session, 2014, March 29 20/40 (50%) 9/40 (22%) 6/40 (15%) 18/51 (35%) 4/51 (8%) 8/51 (16%) 20/69 (29%) n.a. 9/69 (13%)
11 Silent or Asymptomatic AF Cardiovascular Health Study (1) 30% of patients SPAF trial 45% Metrix Investigators study 20% of the episodes were symptomatic Olmsted County Minnesota Silent in 29% of patients, atypical in 38%, symptomatic in 18% 1. Furberg AJC Blackshear MCP Timmermans JACC 2000
12 Detecting and monitoring AF Main challenges: Poor correlation between symptoms and AF episodes AF episodes may be asymptomatic Symptoms may not relate to AF episodes Intermittent monitoring leads to AF undersensing Likelihood of inappropriate decisions concerning anticoagulation and AA drugs therapy Likelihood of inappropriate evaluation of therapy outcome
13 Longterm Continuous Monitoring vs. Standard Methods Comparison of monitoring strategies for AF detection: Extended monitoring results in more AF detection Adapted from A. Arya. PACE 2007; 30: G. Boriani et al. Cardiostim 2008, abstract Ziegler P, et al. Heart Rhythm 2006; 3: Botto GL, et al. J Cardiovasc Electrophysiol 2009; 20: Continuous AF monitoring is currently only possible in ICD/PM patients
14 Atrial fibrillation management Clinical Evidence Many cardiac device patients without history of atrial fibrillation show new or yet undiagnosed AF after implantation >13% of all ICD and pacemaker patients have previously unknown AF * ~23% On 2438 paz. implanted with CRT 23% show AF episodes. * Ricci, RP. et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace ** Camm, AJ. et al., Guidelines for the management of AF: the Task Force for the Management of AF of the European Society of Cardiology (ESC). Europace
15 Israel MD, et al. JACC 2004; Frequency of Asymptomatic AF 110 pacemaker patients with paroxysmal or persistent AF More than one third (38%) of AF episodes were asymptomatic Difficult to know if patients are remaining in sinus rhythm Number of Patients Device Documented AF >48 Hours (19 month follow up) Asymptomatic 30 Symptomatic
16 Clinical implications of AF The presence of atrial high rate events in the pacemakers diagnostics is an independent predictor of total mortality, stroke and chronic atrial fibrillation in patients with sinus node dysfunction. Kaplan-Meier plot of death or non-fatal stroke after 1 year of ancillary study follow-up in patients with AHREs vs those without AHREs; P= MOST indicates Mode Selection Trial; AHRE, atrial high rate episodes. Glotzer T.V. et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke - Report of the atrial diagnostics ancillary study of the Mode selection Trial (MOST).Circulation 2003;107:1614-9
17 AT/AF episodes longer than 24 h were associated with a threefold increased stroke rate. While these data relate to pacemaker recipients, the evidence in ICD recipients is unclear
18 TRENDS: Glotzer Circ A&EP 2009 The relationship between AT/AF and stroke in device patients Purpose: To assess the association between device detected AT/AF and thromboembolic event (TE) among patients with stroke risk factors. Methods: De novo IPG/ICD/CRT, >1 stroke risk factors, w/o persistent AT/AF Observational Results: 2486 pts with mean CHADS 2 score of followed for 1.4 Yrs Device detected AT/AF (>175 bpm for >20 sec) occurred in 24% of pts Annualized TE event rate was 1.2% (40 pts) High AT/AF burden (>5.5 hr) within 30 days was associated with higher TE rate (2.4) and increased risk of TE event (HR 2.2 [0.96, 5.05]; p=0.06) TE Rates for the Overall Study Group (Unadjusted) Hazard Ratios for Thromboembolic Events Associated With AT/AF Burden Adjusted for Stroke Risk Factors and Antithrombotic Therapy High and low burden are separated by the median value of 30 day windows having nonzero AT/AF burden; that is, high corresponds to a burden of >5.5 hours, low corresponds to a burden of 20 seconds to <5.5 hours. *Estimates based on Cox model with time varying AT/AF burden and antithrombotic therapy. Implications: TE risk is low in these device patients despite a moderately high CHADS 2 risk score. Suggestive of a temporal relationship in that high AT/AF burden (>5.5 hrs) on any day in the most recent 30 days doubles the risk for TE Glotzer TV, et al. (TRENDS) Circ A&EP 2009;2:
19 Ischemic Stroke in ASSERT 2580 pacemaker and ICD patients with hypertension and no history of AF 10% experienced asymptomatic AF (episodes of atrial rate >190 beats per minute for more than 6 minutes) within 3 months. Asymptomatic AF was associated with a 2.5 fold increase in the risk for ischemic stroke and systemic embolism (P=0.007). Events (% per year) Risk of Ischemic Stroke or Systemic Embolism, by CHADS2 Score and Presence of Subclinical AF within first 3 months Healey JS, et al. NEJM 2012; 366: AF Present AF Absent 1 2 >2 CHADS2 Score 19
20 ASSERT: Healey NEJM 2012 The relationship between AT/AF and stroke in device patients Purpose: To assess the association between device detected AT/AF and stroke. Methods: De novo IPG/ICD <8 wks, hypertension, w/o AT/AF and anticoagulation Observational Results: 2580 pts with mean CHADS 2 score of 2.29 followed for 2.5 Yrs % pts with >1 Subclinical AF episode (>190 bpm for >6 min) within first 3 months Associated with increased risk of Clinical AF (HR 5.56 [ ]; p<0.001) Associated with increased risk of Ischemic Stroke or Systemic Embolism (HR 2.49 [ ]; p=0.007) Among pts with AT/AF episodes >17.72 hrs, annual rate of stroke or systemic embolism was 4.89 (95% CI, 1.96 to 10.07). Implications: Suggests that the presence of Subclinical AF in the first 3 months increases the risk of stroke or peripheral emboli and also increases the risk of clinically evident AT/AF Cumulative Hazard Cumulative Hazard Risk of Clinical AF Risk of Ischemic Stroke or Systemic Embolism Healey JS, et al. (ASSERT) NEJM 2012;366:120 9.
21 The presence and duration of AF are a determinant TE risk factor Risk of thromboembolic events in patients with pacemakers and history of AF depends on the presence and duration of AF and CHADS2 score. Considering the combination of these parameters is possible to divide the population into two subgroups with a significant difference of thromboembolic risk (0.8% vs 5.0%, p = 0.035)
22 PURPOSE: To assess the association between maximum daily AT/AF burden and risk of stroke The analysis cohort was comprised of 3 clinical databases: TRENDS, PANORAMA and the Italian ClinicalService Project (total of 10,016 eligible patients, with a median follow up time of 24 months) Several cut off points for the maximum Daily AT/AF Burden from Cardiac Compass were used to dichomotize the patients, to enable comparison of the risk for stroke < 5 min vs > 5 min < 1 hr vs > 1 hr < 6 hr vs > 6 hr < 12 hr vs > 12 hr < 23 hr vs > 23 hr the results were adjusted for factors which are known to influence stroke risk, i.e. CHADS2 classification and use of OAC (at baseline)
23 AF Burden and Risk of Stroke AF Burden value Hazard Ratio 95% Confidence Interval P value < 5 vs. > 5 min p=0.041 < 1 vs. > 1 hr to 3.64 p=0.008 < 6 vs. > 6 hr to 3.41 p=0.067 < 12 vs. > 12 hr to 3.22 p=0.090 < 23 vs. > 23 hr to 3.01 p=0.332
24 AF Burden and Risk of Stroke and TIA AF Burden value Hazard Ratio 95% Confidence Interval P value < 5 vs. > 5 min to 3.09 p<0.001 < 1 vs. > 1 hr to 2.90 p=0.003 < 6 vs. > 6 hr to 2.41 p=0.065 < 12 vs. > 12 hr to 2.44 p=0.092 < 23 vs. > 23 hr to 2.56 p=0.1317
25 Daily Maximum Increase in AF Burden For every additional hour increase in the daily maximum of AF burden, the relative risk for stroke increases by about 3% 6 hour increase AF burden implies an increase in risk of stroke of 17% 12 hour increase AF burden implies a 37% increase in risk
26 Intervention Studies for SCAF 1. IMPACT Intensive remote monitoring + SCAF-OAC algorithm vs. usual care 2. ARTESiA Apixaban vs. ASA 3. NOAH Edoxaban vs. Placebo
27 Patients with: SCAF 6 min to 24 hrs Risk factors for stroke (age 75, previous stroke/ TIA/ SE or multiple risk factors)* No clinical AF/not on OAC, no contraindication *New amendment Doubleblind, doubledummy design Apixaban Arm: 5mg or 2.5mg bid (+ placebo aspirin) CONSENT and RANDOMIZE Aspirin Arm: 81 mg OD (+ placebo apixaban) 4000 patients from ~150 hospitals in Canada, USA and Europe Target is 1 4 patients per month at each site Follow up Visits: 1 month and every 6 months ( avg 3 yrs follow up) 1 Efficacy Outcomes: Stroke (including TIA with imaging), Systemic Embolism 1 Safety Outcome: Major Bleed
28 Primary Efficacy: Stroke (including TIA with DWI) (rapid onset of neuro symptoms with no other readily identifiable cause, confirmation of diagnosis e.g., specialist consult or imaging) Systemic Arterial Embolism (clinical signs and symptoms plus at least one objective measure) Primary Safety: ISTH Major Bleeding (fatal, symptomatic in critical area or organ, Hg drop 2 g/dl or transfusion 2 units blood) Central Adjudication by Neurologist Central Adjudication by Neurologist, Cardiologist or Thrombosis specialist Central Adjudication by Neurologist, Cardiologist or Thrombosis specialist
29 Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of AF Ricci et al., Europace 2009;11:54-61 HM & AF Study: pilot italian single center study 166 pt. (121 PM, 22 ICD, 23 CRT-D). Mean FU 488±203 days 42 (26%) pt. with AF ALERT - 33/42 (78%) pt. unscheduled FU (HM detection) - 22/33 (67%) No AF history - 24/33 (73%) asymptomatic - 16/33 (48%) began antiarrhythmics treatment Actionability : 88% - 17/33 (51%) began anticoagulants treatment! Early Detection: 148 days (5 months earlier) before scheduled FU*! Early detection Asymptomatic AF *(every 6 months for ICDs e 12 months for PMs) Follow-Up Mean 148 days gained through HM Next follow-up
30 COMPAS TRIAL Home Monitoring reduces the rate of hospitalizations for atrial arrhythmias and related stroke Population: 538 PPM patients Incidence of hospitalizations for atrial arrhythmias and related stroke n=18 Control group (n=246) p=0.02 n=6 Home Monitoring group (n=248) COMPAS showed a 66% reduction in hospitalizations for atrial arrhythmia and related stroke* *despite the fact that the study was not powered to this assumption 18 events in Control group consisted of 10 atrial arrhythmias and 8 strokes 6 events in HM group consisted of 4 atrial arrhythmias and 2 strokes Mabo P et al. Eur Heart J 2011; doi: /eurheartj/ehr419
31 Atrial Fibrillation in CIEDs and Stroke Relative risk for ischemic stroke appears increased for all types of AF and SCAF Appears to be a stepwise increase in ABSOLUTE risk with greater AF burden There is lack of Temporal Relationship of AF & Thromboembolism Large clinical trials will define the role of OAC in SCAF
32
33 Open issues: 1. Not clear criteria to start anticoagulation - at which AF episode duration? - at which Burden? 2. Not clear criteria when to start or to discontinue OAT - No temporalized correlation AF and TE events clinical risk factors should play a first-line role in making decision!
Subclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationDiagnosing atrial fibrillation using implantable devices
Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC
More informationThe Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Taya V. Glotzer, MD; Emile G. Daoud, MD; D. George Wyse, MD, PhD; Daniel
More informationDevice Diagnostics and Stroke Prevention: State of the Art
Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ
ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart
More informationCausal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
More informationSUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!! Atrial tachycardia «ATRIAL HIGH RATES EPISODES» (AHREs) Episodes
More informationECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
More informationFibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia
Gianluca Botto, FESC Elettrofisiologia Ospedale Sant Anna, Como Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia 20 min Presenter Disclosure Information n n n Research
More informationAtrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.
More informationCausal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationDevice detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
More informationImplantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria
More informationΣτυλιανός Τζέης MD, PhD, FESC
Βραχειάς δια ρκειας ριπε ςυπερκοιλιακη ς ταχυαρρυθμιάς στο Holter ρυθμου η στις συσκευε ςδιαχει ρισης του καρδιακου ρυθμου. Θα χορηγη σουμε αντιθρομβωτικη αγωγη ; Στυλιανός Τζέης MD, PhD, FESC Επιμελητής
More informationMake the Connection A clinical compendium on the relationship between AF, stroke, and early intervention
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention Data that date back to the 1970 s have illustrated the strong relationship between atrial fibrillation
More informationΘα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο
More informationAtrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment
MAEDICA a Journal of Clinical Medicine 2018; 13(4): 261-265 https://doi.org/10.26574/maedica.2018.13.4.261 Mædica - a Journal of Clinical Medicine Invited Editorial Point of View Subclinical Atrial Fibrillation,
More informationThromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationAtrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands
Atrial fibrillation and stroke Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January 2018 Content Stroke what is the problem for patients with AF?
More informationRemote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD
Remote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD Philippe Mabo University Hospital, Rennes, France ESC congress, Paris 30 August 2011 U642 Disclosures Biotronik: research
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAsymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco
Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationConsequences of stroke and AF
Consequences of stroke and AF Lorenzo G Mantovani Center of Pharmacoeconomics University of Naples Center for Public Health Research University of Milan Bicocca Questions Is stroke frequent? Is stroke
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationAF Detection During Drug Development: What Constitutes a Signal
AF Detection During Drug Development: What Constitutes a Signal Peter R. Kowey, FACC, FAHA, FHRS Lankenau Heart Institute Jefferson Medical College Philadelphia, PA Disclosure Dr. Kowey has consulted for
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationI have nothing to disclose.
I have nothing to disclose. Atrial fibrillation in octogenarians and beyond. The magnitude of the problem Etienne Aliot University of Nancy France Population ageing World Population Ageing 1950-2050 Age>
More informationAtrial Fibrillation T. Jared Bunch, MD, FACC
Atrial Fibrillation T. Jared Bunch, MD, FACC Director of Heart Rhythm Services, Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Intermountain Healthcare; Salt Lake City, UT Objectives:
More informationCryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
More informationUTILITY OF THE IMPLANTABLE LOOP RECORDER
UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationSUPPLEMENTARY INFORMATION
Table S1 Sex- specific differences in rate- control and rhythm- control strategies in observational studies Study region Study period Total sample size Sex- specific results Ozcan (2001) 1 Mayo Clinic,
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationDoes AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions
Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions Relationships! Consultant: Medtronic, St Jude, Atricure, Boherringer
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Dr. Lianjie Xiong Dr. Xiong is a PGY2 cardiology pharmacy resident at Vanderbilt University Medical Center in Nashville, TN. She went to Nova Southeastern University and
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationFibrillazione atriale subclinica e rischio di ictus ischemico
Fibrillazione atriale subclinica e rischio di ictus ischemico Background 25% of all ischemic strokes are cryptogenic, and subclinical atrial fibrilla;on (AF) is suspected to be a possible cause in many
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationLa strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole
La strategia diagnostica: il monitoraggio ecg prolungato Michele Brignole ECG monitoring and syncope In-hospital monitoring Holter Monitoring External loop recorder Remote (at home) telemetry Implantable
More informationCLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence
CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On
More informationWhen does enhanced monitoring for atrial fibrillation add value?
When does enhanced monitoring for atrial fibrillation add value? Jonathan P. Piccini, MD, MHS, FHRS Associate Professor of Medicine Duke Clinical Research Institute Duke University Medical Center jonathan.piccini@duke.edu
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationOAC after apparently successfull AF ablation: when, why, and how?
Gulf EP Live 2015 - Dubai January 22-24 / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital,
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationShould AF patients (after ablation) have anticoagulation forever? Can we ever stop it?
The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationFibrillazione atriale: è sempre necessario ricercarla, e come?
Fibrillazione atriale: è sempre necessario ricercarla, e come? Domenico Prisco DMSC Università di Firenze SOD Medicina Interna Interdisciplinare AOU Careggi Firenze 23-10-2018 Disclosure Fees for lectures
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationGRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationFA et Apnée du Sommeil
FA et Apnée du Sommeil La Réunion Octobre 2017 Pascal Defaye CHU Grenoble-Alpes Obstructive Sleep Apnea and AF Incidence of atrial fibrillation (AF), based on presence or absence of OSA. Cumulative frequency
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationEHRA CONSENSUS DOCUMENT
Europace (2017) 0, 1 23 doi:10.1093/europace/eux163 EHRA CONSENSUS DOCUMENT Device-detected subclinical atrial tachyarrhythmias: definition, implications and management an European Heart Rhythm Association
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationAtrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen
Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder The Netherlands Madrid Europace June 2011 Conflict of interests Research grants from Medtronic, SJM, Biotronik, Boston,
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationCan Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015
Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario, Canada Chair,
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationRisk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers
Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More information'Understanding Atrial Fibrillation: New Insights in Pathophysiology
82 nd Annual Scientific Meeting of the Japanese Circulation Society Osaka 2018 'Understanding Atrial Fibrillation: New Insights in Pathophysiology Barbara Casadei, MD DPhil FMedSci FESC British Heart Foundation
More information